Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | TGM1 | P22735 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 5/20 | 0.35 |
| ▸ | CA2 | P00918 | 5/20 | 0.35 |
| ▸ | CTSB | P07858 | 3/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.34 |
| ▸ | HPN | P05981 | 1/20 | 0.33 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900865 | 0.83 | LMNA (0.43) | LMNACA1CA2CTSBCTSS | |
| SCHEMBL9942885 | 0.81 | CTSS (0.38) | F13A1TGM2TGM1CTSBCTSS | |
| SCHEMBL2081430 | 0.81 | F13A1 (0.44) | F13A1TGM2TGM1CTSBCTSS | |
| SCHEMBL51559 | 0.80 | CTSS (0.38) | CTSBCTSSCTSLRORCCTSK | |
| SCHEMBL14235106 | 0.79 | LMNA (0.35) | LMNACA1CA2CTSBCTSS | |
| SCHEMBL63524 | 0.79 | CTSS (0.37) | CTSBCTSSCTSLRORCCTSK | |
| SCHEMBL13691697 | 0.79 | CTSS (0.37) | CTSBCTSSCTSLRORCCTSK | |
| SCHEMBL9901522 | 0.78 | CA1 (0.35) | F13A1TGM2TGM1LMNACA1 | |
| SCHEMBL13657353 | 0.77 | RORC (0.38) | CTSBCTSSCTSLRORCCTSK | |
| SCHEMBL13657354 | 0.75 | RORC (0.37) | CTSBCTSSCTSLRORCCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835411-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835411-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120309698-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| WO-2012078834-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309698-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | F13A1 1085/4885TGM2 3294/4885TGM1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.